Treatment of cancer using a CD33 chimeric antigen receptor

US9777061B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Hilmar Erhard Ebersbach · Basel, CH
• Thomas Huber · Basel, CH
• Julia Jascur · Basel, CH
• Celeste Richardson · Cambridge, US
• Reshma Singh · Cambridge, US
• Huijuan Song · Shanghai, CN
• Qilong Wu · Shanghai, CN
• Jiquan Zhang · Shanghai, CN

Key dates

• Filing date: Jul 21, 2015
• Grant date: Oct 3, 2017
• Expiry date: Jul 21, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/70
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.